Granules India reported a strong Q3 FY26, with revenue up 22% year-over-year and 7% quarter-over-quarter. EBITDA margins improved to 22.2%. The company highlighted the growth in its Finished Dosage segment and regulatory approvals. Future strategies include expanding complex generics and leveraging existing technology platforms. Granules has achieved an ‘A’ rating in climate change from ‘B’ in 2024 from CDP.
Financial Highlights for Q3 FY26
Granules India announced its financial results for the third quarter of fiscal year 2026, showcasing significant growth and improved profitability.
- Revenue: Increased by 22% year-over-year and 7% quarter-over-quarter, reaching ₹13,879 Mn.
- EBITDA: Margins improved by 196 bps year-over-year to 22.2%, despite a loss of ₹248 Mn from Ascelis Peptides.
- Net Profit: Increased by 28% compared to last year.
Segment and Market Performance
The growth in revenue was primarily driven by the Finished Dosage (FD) segment, particularly in North America and Europe. Finished dosages continue to increase in sales across quarters.
- North America: Sales increased by 14% year-over-year.
- Europe: Sales soared by 131% compared to last year, driven by new products and existing customer growth.
Strategic Updates and Initiatives
Granules India continues to focus on strategic initiatives to drive future growth and sustainability.
- R&D: Expenses stood at ₹689 Mn, representing 5.0% of sales.
- Regulatory Approvals: Received 94 approvals till date.
- Sustainability: Achieved the highest “A” rating in climate change from “B” in 2024 from CDP. ICRA also upgraded credit rating from AA- to AA with a positive outlook.
Portfolio Segmentation
The company categorizes its Finished Dosage portfolio into Integrated Generics, Complex Generics, and other opportunities. Granules continues to shift toward complex generics.
Source: BSE
